ExeGi Pharma announces first patient enrollment in the PROF Trial of EXE-346
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
There has been no loss or injury to human life
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Express Scripts to add Zepbound to National Preferred Formulary
The company is assessing the situation and simultaneously undertaking all the requisite action
NATCO temporarily shut down the operations due to cyclone with flooding/water logging of the factory premises
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
Venus Remedies is supplying the drug to many countries like Colombia, Thailand, Tanzania, Morocco, Myanmar, Indonesia, Saudi Arabia, Malaysia, Zimbabwe, Sri Lanka, Pakistan, Kenya, and Botswana
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
Subscribe To Our Newsletter & Stay Updated